Disease / condition

Generalized Pustular Psoriasis,Erythrodermic Psoriasis clinical trials

Free access to 3 studies·1+ countries·Updated daily2 recruiting
3
Total trials
1+
Countries
3+
Sponsors
2
Recruiting
By phase
Phase 32
Phase 41
By status
Recruiting2
Completed1
Top countries
Japan3
Top sponsors
Eli Lilly and Comp...1
Janssen Pharmaceut...1
Takeda1
Recent trials
Latest clinical trials for Generalized Pustular Psoriasis,Erythrodermic Psoriasis
NCT06323356·Phase 3Recruiting
A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
TakedaJapan
NCT06295692·Phase 3Recruiting
A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
Janssen Pharmaceutical K.K.Japan
NCT03942042·Phase 4Completed
A Study of Ixekizumab (LY2439821) in Participants in Japan With Generalized Pustular Psoriasis and Erythrodermic Psoriasis
Eli Lilly and CompanyJapan
About this record

Access comprehensive clinical trial information for Generalized Pustular Psoriasis,Erythrodermic Psoriasis through Pure Global AI's free database. This collection includes 3 clinical trials across multiple phases including Phase 3, Phase 4. Currently, 2 trials are actively recruiting participants.

Research for Generalized Pustular Psoriasis,Erythrodermic Psoriasis is being conducted in Japan and more. Leading sponsors include Eli Lilly and Company and Janssen Pharmaceutical K.K.. Pure Global AI offers free access to clinical trial data from ClinicalTrials.gov, WHO ICTRP, and regional registries worldwide.

Pure Global AI provides free access to 3 clinical trials studying Generalized Pustular Psoriasis,Erythrodermic Psoriasis, aggregated from major global registries including ClinicalTrials.gov, WHO ICTRP, and regional databases.

The trials span multiple phases, from early Phase 1 safety studies to large-scale Phase 3 efficacy trials, conducted across 1+ countries.

Top research sponsors include Eli Lilly and Company, Janssen Pharmaceutical K.K., Takeda, among others.